# Amgen clinical trials: 1,047 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,047 trials with Amgen as lead sponsor, 50 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Amgen: 1,047 rows for $52.35, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/amgen

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,047
- Recruiting or not yet: 50
- Read on: November 19, 2026

## Trials

The 25 newest of 1,047, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921316) |
| November 2, 2026 | NCT07908641 | Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release... | Amgen | Phase 1 | Not yet recruiting | Psoriasis, Arthritis, Psoriatic, Oral Ulcer | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908641) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 8, 2026 | NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Amgen | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866066) |
| October 1, 2026 | NCT07851220 | A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Amgen | Phase 3 | Recruiting | Glomerulonephritis, Membranous | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851220) |
| September 22, 2026 | NCT07832799 | Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | Amgen | Phase 1 | Not yet recruiting | Overweight, Obesity | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832799) |
| September 10, 2026 | NCT07811999 | Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC... | Amgen | Phase 1 | Recruiting | Healthy Participants | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811999) |
| September 4, 2026 | NCT07803679 | A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma | Amgen | Phase 4 | Not yet recruiting | Coronary Artery Disease, Hypercholesterolemia, Atheroma, Atherosclerotic Plaque | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803679) |
| August 21, 2026 | NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Amgen | Phase 3 | Recruiting | Small Cell Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778316) |
| August 4, 2026 | NCT07745907 | A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers | Amgen | Phase 1 | Active not recruiting | Healthy Participants | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745907) |
| July 21, 2026 | NCT07717814 | A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity | Amgen | Phase 1 | Completed | Overweight and Obesity | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717814) |
| July 13, 2026 | NCT07700238 | A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Newly Diagnosed Previously Untreated Primary... | Amgen | Phase 3 | Recruiting | Primary Immune Thrombocytopenia | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700238) |
| July 6, 2026 | NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 3,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684235) |
| July 6, 2026 | NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Amgen | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684144) |
| May 29, 2026 | NCT07614776 | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular... | Amgen | Phase 3 | Recruiting | Neovascular Age-related Macular Degeneration, nAMD | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614776) |
| May 20, 2026 | NCT07598825 | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Amgen | Phase 3 | Recruiting | Autoimmune Hepatitis, AIH | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598825) |
| May 15, 2026 | NCT07590193 | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | Amgen | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590193) |
| May 8, 2026 | NCT07575399 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in... | Amgen | Phase 3 | Recruiting | Obesity or Overweight | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575399) |
| April 22, 2026 | NCT07545226 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. | Amgen | Phase 1 | Completed | Healthy Participants | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545226) |
| April 15, 2026 | NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | Amgen | Phase 1 | Recruiting | Small Cell Lung Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531095) |
| April 13, 2026 | NCT07523711 | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants... | Amgen | Phase 1 | Active not recruiting | Overweight, Obesity | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523711) |
| March 25, 2026 | NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Amgen | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493512) |
| February 27, 2026 | NCT07441252 | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Amgen | Phase 2 | Active not recruiting | Overweight or Obesity and Elevated Liver Fat | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441252) |
| February 27, 2026 | NCT07438405 | An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease | Amgen | Phase 2 | Recruiting | Thyroid Eye Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07438405) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 265 |
| Phase 1/2 | 41 |
| Phase 2 | 242 |
| Phase 2/3 | 5 |
| Phase 3 | 308 |
| Phase 4 | 84 |
| Not applicable | 19 |
| Observational | 81 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 789 |
| Terminated | 121 |
| Active not recruiting | 54 |
| Recruiting | 45 |
| Withdrawn | 16 |
| No longer available | 7 |
| Not yet recruiting | 5 |
| Approved for marketing | 4 |
| Unknown | 4 |
| Available | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 80 |
| Anemia | 62 |
| Arthritis, Rheumatoid | 55 |
| Renal Insufficiency, Chronic | 54 |
| Psoriasis | 51 |
| Multiple Myeloma | 42 |
| Colorectal Neoplasms | 39 |
| Hypercholesterolemia | 35 |
| Hyperparathyroidism, Secondary | 33 |
| Carcinoma, Non-Small-Cell Lung | 33 |
| Obesity | 32 |
| Osteoporosis | 32 |
| Breast Neoplasms | 29 |
| Neoplasm Metastasis | 29 |
| Overweight | 25 |
| Kidney Diseases | 24 |
| Recurrence | 24 |
| Osteoporosis, Postmenopausal | 24 |
| Bone Diseases, Metabolic | 23 |
| Migraine Disorders | 22 |
| Arthritis, Psoriatic | 21 |
| Arthritis | 20 |
| Kidney Failure, Chronic | 20 |
| Lung Neoplasms | 20 |
| Prostatic Neoplasms | 19 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [HVAC contractors in the United States](https://specstream.ai/data/businesses/hvac-contractors/united-states)
- [Colleges and universities in the United States](https://specstream.ai/data/businesses/colleges-and-universities/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
